WindTree Therapeutics has the clinical results it wants—but is missing the bull market, meaning the biotech is exploring strategic options. Amid the market downturn, the biotech is considering a ...

Windtree Therapeutics' roots may have received some urgently needed financial watering last month thanks to a private placement of its stock, but the biotech still doesn’t have enough money to keep ...

WARRINGTON, Pa., May 16, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company ...

WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced major reductions in its outstanding Series C and Series D preferred shares, positioning the company to limit future equity ...

Windtree Therapeutics Inc. drew increased retail chatter on Tuesday after disclosing plans to adopt a cryptocurrency policy that would enable it to accept digital currencies as payment and hold them ...

Seismic Pharmaceutical Holdings, LLC acquires the cardiovascular assets and will pay Windtree 20% of any milestone payments, royalty payments or similar economic interests (including all global ...

Windtree Therapeutics Inc (NASDAQ:WINT) shares are trading higher by 36.5% to $2.03 during Monday’s session after the company regained compliance with Nasdaq’s minimum bid price requirement, ensuring ...

WARRINGTON, Pa., July 1, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute ...

Windtree Therapeutics, Inc. (NASDAQ:WINT) shares are trading higher on Thursday after the company entered a license and supply agreement with Evofem Biosciences, Inc. What To Know: Under the agreement ...

WARRINGTON, Pa., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (OTCID: WINT), a diversified company with several divisions and focused on becoming a ...